Search

Filters

Clear Filters
2:51 PM - 2:58 PM PT

124 - Tracking Changes in B Cell Antibodies in Cervical Cancer Patients Treated with Chemoradiation and Immunotherapy on GOG 9929
Speaker: Kim, Sangwoo, MD - University of California, San Diego, La Jolla, CA
2:58 PM - 3:05 PM PT

125 - Hypofractionated Radiotherapy as a Potential Alternative to Conventional Treatment for Cervical Cancer in Resource-Limited Setting: A Prospective Comparative Analysis
Speaker: Mallum, Abba, MD, PhD, MBBS - Department of Radiotherapy and Oncology, Inkosi Albert Luthuli Central Hospital, Durban, KwaZulu-Natal Na
3:05 PM - 3:12 PM PT

126 - A Real-World Comparison of Moderated Hypofractionated Radiotherapy and Conventional Fractionated Radiotherapy in Cervical Cancer
Speaker: Zeng, Zheng, MD - Peking Union Medical College Hospital, Beijing, Beijing
2:30 PM - 2:40 PM PT

127 - Mid-Treatment ctDNA to Predict Outcomes in Stage IIB-IIIC NSCLC Treated with MRI-Adapted Chemoradiation
Speaker: Hashmi, Ayesha, MD - Mayo Clinic Alix School of Medicine, Rochester, MN
2:40 PM - 2:50 PM PT

128 - Fatal Pulmonary Hemorrhage in Patients Treated with Hypofractionated RT for Stage II-III NSCLC
Speaker: Cooke, Saskia, MD - Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, Noord-Holl
2:50 PM - 3:00 PM PT

129 - Sequential Chemo-Immunotherapy plus Optimized Thoracic Radiotherapy vs. Standard Thoracic Radiotherapy for Elderly and/ or Frail Stage III Non-Small-Cell Lung Cancer: A Randomized Open-Label Controlled Trial of iLCC-3
Speaker: Qi, Wei-Xiang, MD, RT - Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai
3:00 PM - 3:10 PM PT

130 - High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Phase II Immunotherapy Clinical Trials
Speaker: Eustace, Nicholas, MD, PhD - City of Hope National Medical Center, Duarte, CA
3:10 PM - 3:20 PM PT

131 - Gut Microbiota Predictive of Consolidation Immunotherapy Efficacy and Toxicity after Chemoradiotherapy in Lung Cancer
Speaker: Li, Yitong, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing, Beijing
3:20 PM - 3:30 PM PT

132 - Consolidative Radiotherapy with Osimertinib in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: Long-Term Local and Intracranial Control Results from a Phase II Trial
Speaker: Sampath, Sagus, MD - City of Hope Medical Center, Duarte, CA
3:30 PM - 3:40 PM PT

133 - First-Line EGFR-TKIs Combined with Primary-Focus Radiotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): A Real-World Retrospective Study
Speaker: Li, Yan, MD - West China Hospital of Sichuan University, Chengdu, Sichuan
2:30 PM - 2:40 PM PT

134 - Interrogating Contributions of the Sensory Neuroimmune Axis to Treatment Resistance in Head and Neck Squamous Cell Carcinoma
Speaker: Idlett-Ali, Shaquia, MD, PhD, BS - University of Colorado School of Medicine, Aurora, CO
2:40 PM - 2:50 PM PT

135 - IL-17-Producing Gd T Cells Recruited By Cgas-Sting-Dependent CCL20 in Macrophages Drive Radioresistance
Speaker: Kong, Lingyi, MD - Union Hospital Cancer Center, Tongji Medical College, HUST, Wuhan, Hubei